Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Zelda Therapeutics Ltd (ZLDAF)
Zelda Therapeutics Ltd (ZLDAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ZLDAF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5500 +127.27%
on 05/05/23
1.6500 -24.24%
on 06/01/23
+0.5529 (+79.31%)
since 04/12/23
3-Month
0.5500 +127.27%
on 05/05/23
1.6500 -24.24%
on 06/01/23
+0.5216 (+71.61%)
since 02/24/23
52-Week
0.5500 +127.27%
on 05/05/23
2.5300 -50.59%
on 07/15/22
+0.3988 (+46.85%)
since 05/31/22

Most Recent Stories

More News
Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets

/PRNewswire/ -- Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated...

ZLDAF : 1.2500 (-24.24%)
Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

/PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD, OTC-QB: ZLDAF), a global leader in the research, development and commercialization of clinically validated...

ZLDAF : 1.2500 (-24.24%)
Proactive news headlines including Volt Resources, Orthocell, Zelira Therapeutics and Tempus Resources

Sydney, June 21, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

OCC : 4.14 (+3.83%)
ZLDAF : 1.2500 (-24.24%)
TMRR : 0.1050 (-44.74%)
TMRFF : 0.0550 (+3.00%)
RPM : 83.73 (+4.60%)
Proactive news headlines including Shree Minerals, Emperor Energy, SUDA Pharmaceuticals and Zelira Therapeutics

Sydney, June 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

EMP : 23.75 (+1.24%)
ZLDAF : 1.2500 (-24.24%)
ARU : 25.20 (-0.32%)
ARAFF : 0.2489 (+7.05%)
DNK : 2.37 (+0.72%)
DNK.LN : 20.000 (unch)
DNKLY : 0.2395 (-0.21%)
AXE : 97.85 (-0.02%)
ARRXF : 0.3900 (+27.87%)
PAR : 35.02 (+2.07%)
PBIGF : 0.6110 (-4.98%)
KIN : 9.25 (+0.11%)
Proactive news headlines including Element 25, Bellevue Gold, Zelira Therapeutics and St George Mining

Sydney, April 15, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

BELGF : 0.8500 (+0.14%)
ZLDAF : 1.2500 (-24.24%)
FYIRF : 0.1000 (+45.35%)
HLX : 7.03 (+6.03%)
MXC : 11.30 (+4.53%)
MXC.LN : 0.385 (-1.28%)
MGCLF : 0.0049 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1.5167
2nd Resistance Point 1.3833
1st Resistance Point 1.3167
Last Price 1.2500
1st Support Level 1.1167
2nd Support Level 0.9833
3rd Support Level 0.9167

See More

52-Week High 2.5300
Fibonacci 61.8% 1.7736
Fibonacci 50% 1.5400
Fibonacci 38.2% 1.3064
Last Price 1.2500
52-Week Low 0.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar